PA8851901A1 - Compuestos ciclopropilo - Google Patents

Compuestos ciclopropilo

Info

Publication number
PA8851901A1
PA8851901A1 PA20098851901A PA8851901A PA8851901A1 PA 8851901 A1 PA8851901 A1 PA 8851901A1 PA 20098851901 A PA20098851901 A PA 20098851901A PA 8851901 A PA8851901 A PA 8851901A PA 8851901 A1 PA8851901 A1 PA 8851901A1
Authority
PA
Panama
Prior art keywords
cyclopropyl compounds
cyclopropyl
compounds
diabetes
treatment
Prior art date
Application number
PA20098851901A
Other languages
English (en)
Spanish (es)
Inventor
Belen Bueno Melendo Ana
Javier Agejas Chicharro Francisco
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PA8851901A1 publication Critical patent/PA8851901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PA20098851901A 2008-12-19 2009-12-03 Compuestos ciclopropilo PA8851901A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08380341 2008-12-19
US15378109P 2009-02-19 2009-02-19

Publications (1)

Publication Number Publication Date
PA8851901A1 true PA8851901A1 (es) 2010-07-27

Family

ID=40545955

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098851901A PA8851901A1 (es) 2008-12-19 2009-12-03 Compuestos ciclopropilo

Country Status (34)

Country Link
US (1) US8063079B2 (cg-RX-API-DMAC10.html)
EP (1) EP2379517B1 (cg-RX-API-DMAC10.html)
JP (1) JP5497064B2 (cg-RX-API-DMAC10.html)
KR (1) KR101290437B1 (cg-RX-API-DMAC10.html)
CN (1) CN102256952B (cg-RX-API-DMAC10.html)
AR (1) AR074470A1 (cg-RX-API-DMAC10.html)
AU (1) AU2009335931B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0923183B1 (cg-RX-API-DMAC10.html)
CA (1) CA2746746C (cg-RX-API-DMAC10.html)
CO (1) CO6382120A2 (cg-RX-API-DMAC10.html)
CR (1) CR20110342A (cg-RX-API-DMAC10.html)
DK (1) DK2379517T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2011000197A (cg-RX-API-DMAC10.html)
EA (1) EA019055B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP11011150A (cg-RX-API-DMAC10.html)
ES (1) ES2435242T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20130983T1 (cg-RX-API-DMAC10.html)
IL (1) IL213210A (cg-RX-API-DMAC10.html)
JO (1) JO2979B1 (cg-RX-API-DMAC10.html)
MA (1) MA32902B1 (cg-RX-API-DMAC10.html)
MX (1) MX2011006434A (cg-RX-API-DMAC10.html)
MY (1) MY180567A (cg-RX-API-DMAC10.html)
NZ (1) NZ592930A (cg-RX-API-DMAC10.html)
PA (1) PA8851901A1 (cg-RX-API-DMAC10.html)
PE (1) PE20120339A1 (cg-RX-API-DMAC10.html)
PL (1) PL2379517T3 (cg-RX-API-DMAC10.html)
PT (1) PT2379517E (cg-RX-API-DMAC10.html)
SG (1) SG172256A1 (cg-RX-API-DMAC10.html)
SI (1) SI2379517T1 (cg-RX-API-DMAC10.html)
TN (1) TN2011000294A1 (cg-RX-API-DMAC10.html)
TW (1) TWI395748B (cg-RX-API-DMAC10.html)
UA (1) UA104742C2 (cg-RX-API-DMAC10.html)
WO (1) WO2010080333A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201103944B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
WO2015075942A1 (ja) * 2013-11-22 2015-05-28 国立大学法人 東京大学 薬剤送達用のキャリア、コンジュゲートおよびこれらを含んでなる組成物並びにこれらの投与方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282612B1 (en) 2000-05-03 2004-12-29 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
BR0110704A (pt) 2000-05-08 2003-01-28 Hoffmann La Roche Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
MXPA02010795A (es) 2000-05-08 2003-03-27 Hoffmann La Roche Activadores de glucocinasa de fenilamida sustituida por para-amino.
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063179A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
JP4621198B2 (ja) 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ(シクロ)置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004076420A1 (ja) * 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
EA012204B1 (ru) 2004-04-21 2009-08-28 Прозидион Лимитед Три(цикло)замещённые амидные соединения
MX2007001650A (es) 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
AU2005311269B2 (en) * 2004-12-03 2011-11-10 Transtech Pharma, Inc. Heteroaromatic glucokinase activators
BRPI0612582A2 (pt) 2005-07-01 2010-11-23 Novartis Ag combinação de compostos orgánicos
RU2420525C2 (ru) 2005-07-11 2011-06-10 Мицубиси Танабе Фарма Корпорейшн Производные оксимов и их получение
WO2007017649A1 (en) * 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
CA2626475A1 (en) 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
JP2009514836A (ja) 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
JP2009544648A (ja) * 2006-07-24 2009-12-17 エフ.ホフマン−ラ ロシュ アーゲー グルコキナーゼ活性化剤としてのピラゾール類
WO2008084872A1 (ja) * 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation ヒドラゾン誘導体
CN102089291B (zh) 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物

Also Published As

Publication number Publication date
UA104742C2 (uk) 2014-03-11
EP2379517A1 (en) 2011-10-26
CR20110342A (es) 2011-09-14
EA201170845A1 (ru) 2011-12-30
BRPI0923183A8 (pt) 2017-09-12
KR101290437B1 (ko) 2013-07-29
EP2379517B1 (en) 2013-08-28
IL213210A (en) 2015-03-31
US8063079B2 (en) 2011-11-22
CN102256952B (zh) 2013-12-11
BRPI0923183A2 (pt) 2016-02-16
CA2746746C (en) 2013-09-24
DOP2011000197A (es) 2011-09-15
ES2435242T3 (es) 2013-12-17
ECSP11011150A (es) 2011-07-29
TWI395748B (zh) 2013-05-11
JP2012512874A (ja) 2012-06-07
PE20120339A1 (es) 2012-04-16
MY180567A (en) 2020-12-02
PL2379517T3 (pl) 2014-01-31
KR20110086751A (ko) 2011-07-29
ZA201103944B (en) 2012-11-28
WO2010080333A1 (en) 2010-07-15
US20100160395A1 (en) 2010-06-24
EA019055B1 (ru) 2013-12-30
BRPI0923183B1 (pt) 2019-03-19
HRP20130983T1 (hr) 2013-11-22
TW201029999A (en) 2010-08-16
MX2011006434A (es) 2011-07-19
AU2009335931B2 (en) 2012-05-31
MA32902B1 (fr) 2011-12-01
AU2009335931A1 (en) 2011-07-07
NZ592930A (en) 2013-01-25
DK2379517T3 (da) 2013-09-30
SG172256A1 (en) 2011-07-28
IL213210A0 (en) 2011-07-31
AR074470A1 (es) 2011-01-19
TN2011000294A1 (en) 2012-12-17
CO6382120A2 (es) 2012-02-15
JP5497064B2 (ja) 2014-05-21
CA2746746A1 (en) 2010-07-15
SI2379517T1 (sl) 2013-10-30
CN102256952A (zh) 2011-11-23
PT2379517E (pt) 2013-11-21
JO2979B1 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
DOP2012000006A (es) Agonista de gpr119
ECSP11011151A (es) Compuestos purina
MY153915A (en) Organic compounds
CL2007003758A1 (es) Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer.
EA201170772A1 (ru) Органические соединения
IN2015DN00185A (cg-RX-API-DMAC10.html)
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
BR112015007310A2 (pt) compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
EA201270590A1 (ru) Ингибиторы акт
EA201190125A1 (ru) Таблетки для комбинированной терапии
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
BR112012024586A2 (pt) compostos de purina
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
CR20110342A (es) Compuestos ciclopropilo
CL2011001850A1 (es) Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto.
MY150776A (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
CL2009001493A1 (es) Compuestos derivados de 3-cianopirrolidin-fenil-oxazolidinonas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de infecciones bacterianas.
EA201300160A1 (ru) 2,3,5-тризамещенные тиофены и их применение
MX2013006185A (es) Compuestos de 6-(piridinilmetoxi) -pirrolopiridina 3-sustituidos.
HN2011001702A (es) Compuestos de ciclopropilo
TN2010000583A1 (en) Organic compounds
CL2009002112A1 (es) Un compuesto derivado de carbamoiloxi-arilalcanoil-arilpiperazina; composicion farmaceutica que comprende a dicho compuesto, util para el tratamiento del dolor, la ansiedad o la depresion.